Bristol-Myers Squibb Company (BMY) Q2 2014 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Up 0.28%

Bristol Myers Squibb's earnings report shows a positive surprise in EPS, which contributed to a slight increase in stock price. The management's optimistic tone regarding their pipeline suggests potential for future growth, although the lack of revenue data and guidance leaves some uncertainty. Investors may view the EPS beat as a sign of resilience in the company's performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.48	N/A	+7.62%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in their product offerings and future growth potential. However, they did not provide specific guidance for the upcoming quarters.

Management highlighted the continued strength in their pipeline.

They emphasized a commitment to innovation and addressing unmet medical needs.

Bristol Myers Squibb Beats on EPS, Stock Up 0.28%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Up 0.28%

Key numbers

Management commentary